TY - JOUR
T1 - Long-term consequences of perinatal fatty acid amino hydrolase inhibition
AU - Wu, Chia Shan
AU - Morgan, Daniel
AU - Jew, Chris P.
AU - Haskins, Chris
AU - Andrews, Mary Jeanette
AU - Leishman, Emma
AU - Spencer, Corinne M.
AU - Czyzyk, Traci
AU - Bradshaw, Heather
AU - MacKie, Ken
AU - Lu, Hui Chen
PY - 2014/3
Y1 - 2014/3
N2 - Background and Purpose Fatty acid amide hydrolase inhibitors show promise as a treatment for anxiety, depression and pain. Here we investigated whether perinatal exposure to URB597, a fatty acid amide hydrolase inhibitor, alters brain development and affects behaviour in adult mice. Experimental Approach Mouse dams were treated daily from gestational day 10.5 to 16.5 with 1, 3 or 10 mg kg-1 URB597. MS was used to measure a panel of endocannabinoids and related lipid compounds and brain development was assessed at embryonic day 16.5. Separate cohorts of mouse dams were treated with 10 mg kg-1 URB597, from gestational day 10.5 to postnatal day 7, and the adult offspring were assessed with a battery of behavioural tests. Key Results Perinatal URB597 exposure elevated anandamide and related N-acyl amides. URB597 did not induce signs of toxicity or affect dam weight gain, neurogenesis or axonal development at embryonic day 16.5. It did lead to subtle behavioural deficits in adult offspring, manifested by reduced cocaine-conditioned preference, increased depressive behaviours and impaired working memory. Anxiety levels, motor function and sensory-motor gating were not significantly altered. Conclusions and Implications Taken together, the present results highlight how exposure to elevated levels of anandamide and related N-acyl amides during brain development can lead to subtle alterations in behaviour in adulthood. Linked Articles This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.
AB - Background and Purpose Fatty acid amide hydrolase inhibitors show promise as a treatment for anxiety, depression and pain. Here we investigated whether perinatal exposure to URB597, a fatty acid amide hydrolase inhibitor, alters brain development and affects behaviour in adult mice. Experimental Approach Mouse dams were treated daily from gestational day 10.5 to 16.5 with 1, 3 or 10 mg kg-1 URB597. MS was used to measure a panel of endocannabinoids and related lipid compounds and brain development was assessed at embryonic day 16.5. Separate cohorts of mouse dams were treated with 10 mg kg-1 URB597, from gestational day 10.5 to postnatal day 7, and the adult offspring were assessed with a battery of behavioural tests. Key Results Perinatal URB597 exposure elevated anandamide and related N-acyl amides. URB597 did not induce signs of toxicity or affect dam weight gain, neurogenesis or axonal development at embryonic day 16.5. It did lead to subtle behavioural deficits in adult offspring, manifested by reduced cocaine-conditioned preference, increased depressive behaviours and impaired working memory. Anxiety levels, motor function and sensory-motor gating were not significantly altered. Conclusions and Implications Taken together, the present results highlight how exposure to elevated levels of anandamide and related N-acyl amides during brain development can lead to subtle alterations in behaviour in adulthood. Linked Articles This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.
UR - http://www.scopus.com/inward/record.url?scp=84895741693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895741693&partnerID=8YFLogxK
U2 - 10.1111/bph.12500
DO - 10.1111/bph.12500
M3 - Article
C2 - 24730060
AN - SCOPUS:84895741693
SN - 0007-1188
VL - 171
SP - 1420
EP - 1434
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 6
ER -